ArticleJournal of agricultural and food chemistry2025
Empowering Gliadin Detection: A Visible-Code Semiquantitative Lateral Flow System for Rapid and Reliable Results.
Article in Journal of agricultural and food chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wheat is a global staple, but its main protein, "gluten," can trigger severe reactions in people with celiac disease, an autoimmune disorder affecting around 1% of the population. The only treatment is a lifelong gluten-free diet. Gliadin, a gluten component, is the primary trigger and is difficult to detect due to its low solubility. This makes it challenging for celiac patients to safely eat out or to enjoy diverse foods. To address this, we developed LEO (Lateral flow Enhanced by Optical imaging), a portable gluten detection system combining lateral flow assays with smartphone-based image analysis. LEO uses IoT-enhanced technology to deliver results in under 3 min, accurately quantifying gliadin with over 98% accuracy and sensitivity below the FDA's 20 ppm threshold. In real-world trials, LEO successfully detected hidden gluten in mislabeled "gluten-free" restaurant dishes. With its fast, accurate results and user-friendly design, LEO supports safer food choices for individuals with celiac disease and is suitable for personal, clinical, industrial, and regulatory use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.